Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GUARDIAN long-term vamorolone safety and effectiveness study in Duchenne muscular dystrophy
NL-OMON60825Phase 4Active, not recruiting
- Sponsor
- Santhera Pharmaceuticals
- Start
- Mar 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of vamorolone in Duchenne muscular dystrophy (DMD), sponsored by Santhera Pharmaceuticals. Primary endpoint: Number of vertebral fractures per 1000 person-years. Started Mar 2025; status: active, not recruiting.
02
Drugs
vamorolone
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NL-OMON60825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60825.